HOME >> MEDICINE >> NEWS
Anti-inflammatory drug's potentially deadly side effect found to be rare

Scientists have completed an extensive study of more than 3,000 patients who received a promising anti-inflammatory drug, natalizumab, that was linked to three cases of a serious brain infection in large clinical trials halted in early 2005.

The new study found no new cases of progressive multifocal leukoencephalopathy (PML) and confirmed the three previously identified cases of PML associated with use of the drug. One fatal and one nonfatal case of PML occurred in a trial using natalizumab as a multiple sclerosis treatment; a second fatality happened in a trial that used the drug to treat patients with Crohn's disease, an inflammatory bowel disorder.

"Our analysis suggests about one in every1,000 people who took natalizumab contracted this disease; however, there weren't enough patients exposed to the drug to allow us to precisely estimate the risk, which could be as low as one in 5,000 or as high as one in 300," says senior author David Clifford, M.D., the Melba and Forest Seay Professor of Clinical Neuropharmacology in Neurology at Washington University School of Medicine in St. Louis.

The results of the study, along with two separate studies of natalizumab's effectiveness as an MS treatment, are published in this week's issue of The New England Journal of Medicine.

The brand name of natalizumab, which was jointly developed by Biogen and Elan Pharmaceuticals, is Tysabri. The drug is a monoclonal antibody that binds to inflammatory immune T cells and prevents them from crossing membranes that protect the brain and the central nervous system. Prior to the studies that were halted last year, earlier studies showed a 66 percent reduction in the rate of relapses in MS patients treated with the natalizumab, which has to be injected on a monthly basis.

Clifford predicts that his group's report and the other studies of natalizumab will be important elements in "lively" discussions to be held by the Food and Drug Administration reg
'"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
1-Mar-2006


Page: 1 2 3 4

Related medicine news :

1. Anti-inflammatory drug prevents liver cancer in at-risk liver patients
2. Anti-inflammatory drugs following hip replacement surgery could harm rather than help
3. Anti-inflammatory function of Alzheimers disease drugs revealed
4. A drugs brand name skews patient treatment choices
5. Chemical maps hint at drugs effects on schizophrenia
6. Study to test drugs potential to preserve insulin production in newly diagnosed type 1 diabetics
7. Trial demonstrates new drugs effectiveness against psoriasis
8. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
9. STAMP system can help professionals to identify potentially violent individuals
10. Women with breast cancer do not get potentially life-saving information, survey reveals
11. U-M study finds some prostate cancer patients potentially overtreated

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anti inflammatory drug potentially deadly side effect found rare

(Date:9/2/2015)... ... 03, 2015 , ... The Aspen Clinic (TAC), located in Basalt, ... kick-starting and inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, ... mind-body approach to fitness - we are much more than a gym. Our ...
(Date:9/2/2015)... ... September 03, 2015 , ... One can hardly argue against the fact ... do laptops and personal computers. These devices are being used as GPS, to make ... of mobile dating apps, STD positive singles can now join the prestigious social ranks ...
(Date:9/2/2015)... , ... September 03, 2015 , ... ... to determine who among America’s policymakers, public servants, activists, corporate executives, entrepreneurs, health ... health care. This year, that process led the magazine to tap the National ...
(Date:9/2/2015)... ... September 02, 2015 , ... Chris Harrison of Harrison’s ... “It was a simple decision, really,” says Chris. “We have a lot of repeat ... the brands that work best for them—so we’ve given them the convenience of ordering ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading ... two leaders who will deliver keynote presentations at the upcoming Digital Healthcare Innovation ... Hotel in Boston. , Larry Renfro, CEO of Optum, will deliver the morning ...
Breaking Medicine News(10 mins):Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3
(Date:9/2/2015)... Sept. 2, 2015 About Neuroendovascular Coil ... to treat an unruptured and ruptured brain aneurysm ... treatment is either known as an endovascular coiling ... coil blocks the blood flow in an aneurysm. ... general anaesthesia by an interventional neuroradiologist using fluoroscopic ...
(Date:9/2/2015)... BOULDER, Colo. , Sept. 2, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Securities Healthcare Conference in Boston.  The public is ... webcast on the Array BioPharma website.Event: Wells Fargo ... , Thursday, September 10, 2015Time:  , 10:20 a.m. ...
(Date:9/2/2015)... Transaction Highlights: ... profitable specialty products , Expands pipeline with ... 11 product applications pending at the FDA, of ... Provides medium and longer term growth potential with ... substances , Adds development expertise in difficult ...
Breaking Medicine Technology:Global Neuroendovascular Coil Market 2015-2019 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6
Cached News: